Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free CCCC Stock Alerts

C4 Therapeutics (CCCC) Financials

C4 Therapeutics logo
$3.58 -0.11 (-2.98%)
Closing price 07/20/2026 04:00 PM Eastern
Extended Trading
$3.57 -0.01 (-0.22%)
As of 07/20/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for C4 Therapeutics

Annual Income Statements for C4 Therapeutics

This table shows C4 Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -43 -66 -84 -128 -128 -105 -105
Consolidated Net Income / (Loss)		 -34 -66 -84 -128 -132 -105 -105
Net Income / (Loss) Continuing Operations		 -34 -66 -84 -128 -132 -105 -105
Total Pre-Tax Income 		-33 -67 -84 -128 -131 -105 -105
Total Operating Income		 -35 -60 -82 -130 -139 -120 -115
Total Gross Profit		 21 33 46 31 21 36 36
Total Revenue		 21 33 46 31 21 36 36
Operating Revenue		 21 33 46 31 21 36 36
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 57 94 128 161 160 155 151
Selling, General & Admin Expense		 8.77 15 33 43 42 42 36
Research & Development Expense		 48 78 95 118 118 111 104
Impairment Charge		 - - - - - - 11
Restructuring Charge		 - - - - 0.00 2.44 0.00
Total Other Income / (Expense), net		 2.16 -6.51 -1.76 1.36 7.82 14 10
Interest & Investment Income		 2.16 0.39 0.39 3.58 9.81 14 10
Income Tax Expense		 0.80 -0.63 - 0.00 1.28 0.13 0.12
Basic Earnings per Share		 ($31.03) ($5.83) ($1.82) ($2.62) ($2.67) ($1.52) ($1.27)
Weighted Average Basic Shares Outstanding		 1.37M 11.37M 46.04M 48.86M 49.64M 69.37M 82.89M
Diluted Earnings per Share		 ($31.03) ($5.83) ($1.82) ($2.62) ($2.67) ($1.52) ($1.27)
Weighted Average Diluted Shares Outstanding		 1.37M 11.37M 46.04M 48.86M 49.64M 69.37M 82.89M
Weighted Average Basic & Diluted Shares Outstanding		 1.37M 11.37M 46.04M 49.05M 68.60M 70.99M 97.58M

Quarterly Income Statements for C4 Therapeutics

This table shows C4 Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -26 -34 -29 -18 -25 -34 -26 -26 -32 -20 -25
Consolidated Net Income / (Loss)		 -27 -35 -28 -18 -25 -35 -26 -26 -32 -20 -25
Net Income / (Loss) Continuing Operations		 -27 -35 -28 -18 -25 -35 -26 -26 -32 -20 -25
Total Pre-Tax Income 		-26 -34 -28 -18 -25 -34 -26 -26 -32 -20 -25
Total Operating Income		 -28 -37 -32 -21 -28 -38 -29 -29 -34 -23 -28
Total Gross Profit		 11 3.26 3.04 12 15 5.18 7.24 6.46 11 11 6.15
Total Revenue		 11 3.26 3.04 12 15 5.18 7.24 6.46 11 11 6.15
Operating Revenue		 11 3.26 3.04 12 15 5.18 7.24 6.46 11 11 6.15
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 39 41 35 33 44 43 36 35 46 34 34
Selling, General & Admin Expense		 11 10 10 9.70 12 10 9.33 8.77 8.92 9.18 9.33
Research & Development Expense		 28 30 23 24 32 33 27 26 26 25 25
Total Other Income / (Expense), net		 1.77 2.95 3.86 3.73 3.58 3.27 2.84 2.48 2.25 2.78 2.66
Interest & Investment Income		 2.56 2.95 3.86 3.73 3.58 3.27 2.84 2.48 2.25 2.78 2.66
Basic Earnings per Share		 ($0.55) ($0.68) ($0.41) ($0.26) ($0.35) ($0.50) ($0.37) ($0.37) ($0.44) ($0.09) ($0.20)
Weighted Average Basic Shares Outstanding		 49.21M 49.64M 68.43M 68.81M 69.63M 69.37M 70.83M 71.01M 72.56M 82.89M 126.07M
Diluted Earnings per Share		 ($0.55) ($0.68) ($0.41) ($0.26) ($0.35) ($0.50) ($0.37) ($0.37) ($0.44) ($0.09) ($0.20)
Weighted Average Diluted Shares Outstanding		 49.21M 49.64M 68.43M 68.81M 69.63M 69.37M 70.83M 71.01M 72.56M 82.89M 126.07M
Weighted Average Basic & Diluted Shares Outstanding		 49.28M 68.60M 68.81M 69.34M 70.59M 70.99M 71.01M 71.17M 96.91M 97.58M 110.57M

Annual Cash Flow Statements for C4 Therapeutics

This table details how cash moves in and out of C4 Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 54 91 -105 -46 97 -71 19
Net Cash From Operating Activities		 56 -67 -87 -106 -107 -65 -99
Net Cash From Continuing Operating Activities		 56 -67 -87 -106 -107 -65 -99
Net Income / (Loss) Continuing Operations		 -34 -66 -84 -128 -132 -105 -105
Consolidated Net Income / (Loss)		 -34 -66 -84 -128 -132 -105 -105
Depreciation Expense		 1.60 1.62 1.49 1.68 1.88 1.82 1.96
Amortization Expense		 0.33 0.31 2.60 1.43 -3.38 -5.40 -2.74
Non-Cash Adjustments To Reconcile Net Income		 2.80 10 22 36 34 36 30
Changes in Operating Assets and Liabilities, net		 85 -13 -29 -17 -6.86 7.65 -23
Net Cash From Investing Activities		 -1.62 -191 -189 58 158 -51 -8.60
Net Cash From Continuing Investing Activities		 -1.62 -191 -189 58 158 -51 -8.60
Purchase of Property, Plant & Equipment		 -1.35 -0.65 -1.28 -5.50 -1.71 -0.18 -0.61
Purchase of Investments		 -79 -294 -538 -220 -130 -284 -227
Sale and/or Maturity of Investments		 79 104 350 283 290 233 219
Net Cash From Financing Activities		 0.24 349 171 1.15 45 45 126
Net Cash From Continuing Financing Activities		 0.24 349 171 1.15 45 45 126
Repayment of Debt		 0.00 12 -0.11 0.37 -12 0.38 0.27
Repurchase of Common Equity		 -0.03 -0.19 - 0.00 -0.11 -0.19 -0.19
Issuance of Common Equity		 0.00 195 - 0.00 58 44 126
Other Financing Activities, net		 0.27 0.16 2.33 0.78 0.06 0.78 0.11

Quarterly Cash Flow Statements for C4 Therapeutics

This table details how cash moves in and out of C4 Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 16 66 -37 -17 -13 -4.15 -4.21 27 -19 16 -13
Net Cash From Operating Activities		 -31 -24 -18 -4.97 -24 -18 -33 -12 -31 -22 -30
Net Cash From Continuing Operating Activities		 -31 -24 -18 -4.97 -24 -18 -33 -12 -31 -22 -30
Net Income / (Loss) Continuing Operations		 -27 -35 -28 -18 -25 -35 -26 -26 -32 -20 -25
Consolidated Net Income / (Loss)		 -27 -35 -28 -18 -25 -35 -26 -26 -32 -20 -25
Depreciation Expense		 0.45 0.43 0.45 0.45 0.44 0.48 0.46 0.62 0.46 0.43 0.40
Amortization Expense		 -1.04 -0.97 -1.27 -1.67 -1.39 -1.08 0.87 -2.23 -0.52 -0.86 -1.09
Non-Cash Adjustments To Reconcile Net Income		 10 7.92 7.79 7.98 10 9.87 5.51 8.31 17 -0.34 4.11
Changes in Operating Assets and Liabilities, net		 -13 3.36 3.27 5.98 -8.97 7.38 -14 7.27 -16 -0.89 -8.24
Net Cash From Investing Activities		 58 32 -53 -12 0.16 14 29 39 4.09 -81 16
Net Cash From Continuing Investing Activities		 58 32 -53 -12 0.16 14 29 39 4.09 -81 16
Purchase of Property, Plant & Equipment		 -0.60 -0.16 - - 0.01 0.00 0.00 - -0.41 -0.01 -0.06
Purchase of Investments		 -32 -38 -108 -67 -69 -41 -26 -22 -47 -133 -41
Sale and/or Maturity of Investments		 90 70 54 56 69 54 55 61 51 52 57
Net Cash From Financing Activities		 -11 58 35 0.14 11 0.11 -0.05 - 7.77 119 0.46
Net Cash From Continuing Financing Activities		 -11 58 35 0.14 11 0.11 -0.05 - 7.77 119 0.46
Repayment of Debt		 -11 -0.00 0.08 - 0.30 0.00 0.11 - 0.16 0.00 0.06
Repurchase of Common Equity		 -0.02 - -0.11 - -0.09 - -0.16 - -0.02 -0.01 -0.20
Other Financing Activities, net		 - - 0.52 0.14 0.01 0.11 0.00 - 0.11 - 0.61

Annual Balance Sheets for C4 Therapeutics

This table presents C4 Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 118 400 507 431 376 350 359
Total Current Assets		 97 381 326 288 271 258 258
Cash & Equivalents		 91 182 76 30 127 55 75
Short-Term Investments		 0.00 190 233 246 127 189 174
Accounts Receivable		 4.62 4.48 5.72 1.47 12 3.10 2.40
Prepaid Expenses		 1.60 4.84 11 9.93 5.71 9.76 7.17
Plant, Property, & Equipment, net		 4.46 3.32 3.11 7.40 7.13 5.84 4.74
Total Noncurrent Assets		 17 16 178 136 98 86 96
Long-Term Investments		 - 0.00 142 61 28 22 49
Other Noncurrent Operating Assets		 14 13 32 72 67 60 44
Other Noncurrent Nonoperating Assets		 2.58 2.58 3.28 3.28 3.44 3.44 3.44
Total Liabilities & Shareholders' Equity		 118 400 507 431 376 350 359
Total Liabilities		 119 119 117 142 130 134 102
Total Current Liabilities		 34 44 51 45 43 45 33
Accounts Payable		 5.39 5.68 4.51 1.17 1.45 1.33 0.86
Accrued Expenses		 6.67 9.52 14 20 21 19 13
Current Deferred Revenue		 21 28 32 17 15 19 12
Other Current Liabilities		 0.88 1.04 1.33 4.70 5.22 5.77 6.37
Total Noncurrent Liabilities		 86 75 66 97 88 88 69
Noncurrent Deferred Revenue		 73 54 24 17 22 28 16
Other Noncurrent Operating Liabilities		 13 12 31 71 66 60 54
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -112 281 390 289 246 216 257
Total Preferred & Common Equity		 -112 281 390 289 246 216 257
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -112 281 390 289 246 216 257
Common Stock		 5.53 465 658 689 775 850 995
Retained Earnings		 -117 -184 -268 -396 -528 -634 -739
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.01 -0.78 -4.14 -0.13 0.05 0.05

Quarterly Balance Sheets for C4 Therapeutics

This table presents C4 Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 333 398 381 376 320 297 265 329
Total Current Assets		 224 280 276 273 233 225 207 245
Cash & Equivalents		 61 90 73 60 51 78 59 61
Short-Term Investments		 156 169 191 196 164 136 133 174
Accounts Receivable		 0.50 14 1.17 10 8.03 2.16 6.54 2.88
Prepaid Expenses		 6.62 7.80 11 7.25 9.42 8.02 8.44 6.82
Plant, Property, & Equipment, net		 7.29 6.76 6.57 6.21 5.48 5.54 5.13 4.49
Total Noncurrent Assets		 102 112 98 97 82 66 53 79
Long-Term Investments		 30 41 32 29 20 8.42 7.88 33
Other Noncurrent Operating Assets		 69 68 63 64 58 54 42 43
Other Noncurrent Nonoperating Assets		 3.45 3.44 3.44 3.44 3.44 3.44 3.44 3.44
Total Liabilities & Shareholders' Equity		 333 398 381 376 320 297 265 329
Total Liabilities		 117 140 134 133 124 122 111 95
Total Current Liabilities		 30 55 54 43 41 44 36 27
Accounts Payable		 1.28 1.63 0.91 1.50 0.68 2.22 1.33 0.77
Accrued Expenses		 15 13 11 15 13 14 11 9.83
Current Deferred Revenue		 8.42 35 37 21 22 23 17 10
Other Current Liabilities		 5.09 5.36 5.49 5.63 5.92 6.07 6.22 6.52
Total Noncurrent Liabilities		 87 85 80 90 84 78 75 67
Noncurrent Deferred Revenue		 20 21 17 29 25 21 20 15
Other Noncurrent Operating Liabilities		 67 64 63 61 58 57 55 52
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 216 258 247 243 195 174 154 234
Total Preferred & Common Equity		 216 258 247 243 195 174 154 234
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 216 258 247 243 195 174 154 234
Common Stock		 711 815 822 841 855 860 873 998
Retained Earnings		 -494 -557 -574 -599 -660 -686 -718 -764
Accumulated Other Comprehensive Income / (Loss)		 -0.90 -0.38 -0.44 0.46 0.04 -0.03 0.09 -0.32

Annual Metrics And Ratios for C4 Therapeutics

This table displays calculated financial ratios and metrics derived from C4 Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 55.25% 37.93% -32.08% -33.25% 71.44% 1.02%
EBITDA Growth		 0.00% -91.49% -21.58% -66.31% -8.27% 12.34% 5.70%
EBIT Growth		 0.00% -86.52% -24.21% -61.80% -4.62% 13.97% 3.53%
NOPAT Growth		 0.00% -70.51% -35.87% -57.71% -7.33% 13.97% 3.67%
Net Income Growth		 0.00% -94.54% -26.47% -52.79% -3.37% 20.51% 0.31%
EPS Growth		 0.00% 81.21% 68.78% -43.96% -1.91% 43.07% 16.45%
Operating Cash Flow Growth		 0.00% -220.92% -29.32% -21.82% -0.85% 39.01% -51.47%
Free Cash Flow Firm Growth		 0.00% 0.00% -63.31% -21.78% 7.02% 30.57% -34.39%
Invested Capital Growth		 0.00% 11.34% 34.81% 27.04% 1.66% -40.24% 19.67%
Revenue Q/Q Growth		 0.00% 0.00% 34.78% 0.00% 2.00% 0.00% 19.39%
EBITDA Q/Q Growth		 0.00% 0.00% 5.51% 0.00% 0.02% 0.00% 11.27%
EBIT Q/Q Growth		 0.00% 0.00% 4.25% 0.00% 0.62% 0.00% 11.22%
NOPAT Q/Q Growth		 0.00% 0.00% 4.25% 0.00% 0.62% 0.00% 11.22%
Net Income Q/Q Growth		 0.00% 0.00% 6.82% 0.00% 1.80% 0.00% 11.83%
EPS Q/Q Growth		 0.00% 0.00% -106.26% 0.00% 2.91% 0.00% 24.40%
Operating Cash Flow Q/Q Growth		 0.00% -20.17% -4.92% 0.00% 4.57% 0.00% -4.46%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -46.02% -52.92% 0.00% -4.79%
Invested Capital Q/Q Growth		 0.00% 0.00% 24.64% 0.00% -15.25% 0.00% 9.92%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -156.79% -193.38% -170.46% -417.39% -677.06% -346.20% -322.71%
Operating Margin		 -165.81% -182.10% -179.39% -416.56% -669.84% -336.15% -320.53%
EBIT Margin		 -165.81% -199.20% -179.39% -427.37% -669.84% -336.15% -320.53%
Profit (Net Income) Margin		 -159.48% -199.83% -183.23% -412.19% -638.34% -295.96% -292.08%
Tax Burden Percent		 102.41% 99.07% 100.00% 100.00% 100.98% 100.12% 100.12%
Interest Burden Percent		 93.92% 101.26% 102.14% 96.45% 94.38% 87.94% 91.02%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 3,522.62% -47.41% -25.03% -37.76% -49.50% -45.58% -44.44%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -29.98% -25.51% -18.11% -28.35% -34.44% -32.95% -32.52%
Return on Assets (ROA)		 -28.83% -25.59% -18.50% -27.34% -32.82% -29.01% -29.63%
Return on Common Equity (ROCE)		 407,441.68% -28.61% -25.03% -37.76% -49.50% -45.58% -44.44%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% -48.76% 0.00%
Net Operating Profit after Tax (NOPAT)		 -25 -42 -57 -91 -97 -84 -81
NOPAT Margin		 -116.07% -127.47% -125.57% -291.59% -468.88% -235.30% -224.37%
Net Nonoperating Expense Percent (NNEP)		 -9.97% -10.50% -6.53% -9.70% -11.46% -7.77% -8.52%
Return On Investment Capital (ROIC_SIMPLE)		 22.16% -14.55% -14.36% -30.15% -39.54% -38.77% -31.43%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 41.04% 45.80% 72.63% 137.60% 202.74% 118.38% 100.69%
R&D to Revenue		 224.77% 236.30% 206.76% 378.96% 567.09% 310.92% 289.98%
Operating Expenses to Revenue		 265.81% 282.10% 279.39% 516.56% 769.84% 436.15% 420.53%
Earnings before Interest and Taxes (EBIT)		 -35 -66 -82 -133 -139 -120 -115
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -34 -64 -78 -130 -141 -123 -116
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 5.08 4.02 1.00 1.13 1.18 0.72
Price to Tangible Book Value (P/TBV)		 0.00 5.08 4.02 1.00 1.13 1.18 0.72
Price to Revenue (P/Rev)		 8.53 42.95 34.20 9.28 13.41 7.14 5.15
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 9.49 32.05 24.57 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 3.65 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.04 0.03 0.04 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.04 0.03 0.03 0.00 0.00 0.00
Financial Leverage		 96.20 -1.63 -1.21 -1.14 -1.15 -1.20 -1.21
Leverage Ratio		 -122.17 1.85 1.35 1.38 1.51 1.57 1.50
Compound Leverage Factor		 -114.74 1.88 1.38 1.33 1.42 1.38 1.36
Debt to Total Capital		 0.00% 3.46% 2.69% 3.82% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.76% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 3.46% 2.69% 3.06% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -11,466.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 11,566.43% 96.54% 97.31% 96.18% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.16 -0.14 -0.09 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 5.63 5.65 2.51 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.16 -0.14 -0.07 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.24 -0.19 -0.13 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 8.55 7.67 3.59 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.24 -0.19 -0.10 0.00 0.00 0.00
Altman Z-Score		 -0.64 7.07 7.48 -0.33 -1.12 -1.69 -2.00
Noncontrolling Interest Sharing Ratio		 -11,466.43% 39.67% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 2.88 8.69 6.36 6.46 6.34 5.71 7.81
Quick Ratio		 2.83 8.58 6.15 6.23 6.21 5.49 7.60
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -53 -87 -105 -98 -68 -91
Operating Cash Flow to CapEx		 4,324.57% -10,346.00% -6,810.10% -1,927.57% -6,255.15% -36,198.33% -16,259.31%
Free Cash Flow to Firm to Interest Expense		 0.00 -43.11 -40.34 0.00 -49.14 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -54.72 -40.54 0.00 -53.58 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -55.25 -41.14 0.00 -54.44 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.18 0.13 0.10 0.07 0.05 0.10 0.10
Accounts Receivable Turnover		 4.62 7.29 8.98 8.65 3.13 4.78 13.06
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 4.79 8.53 14.24 5.92 2.86 5.49 6.79
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 78.92 50.07 40.66 42.19 116.70 76.42 27.94
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 78.92 50.07 40.66 42.19 116.70 76.42 27.94
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -94 -83 -54 -40 -39 -55 -44
Invested Capital Turnover		 -0.23 -0.37 -0.66 -0.66 -0.53 -0.76 -0.73
Increase / (Decrease) in Invested Capital		 0.00 11 29 15 0.66 -16 11
Enterprise Value (EV)		 203 1,064 1,125 -37 -3.25 -13 -112
Market Capitalization		 182 1,426 1,566 289 278 254 185
Book Value per Share		 ($81.61) $6.53 $8.01 $5.92 $4.99 $3.06 $2.65
Tangible Book Value per Share		 ($81.61) $6.53 $8.01 $5.92 $4.99 $3.06 $2.65
Total Capital		 -0.97 291 400 301 246 216 257
Total Debt		 0.00 10 11 11 0.00 0.00 0.00
Total Long-Term Debt		 0.00 10 11 9.20 0.00 0.00 0.00
Net Debt		 -91 -362 -441 -326 -282 -267 -297
Capital Expenditures (CapEx)		 1.29 0.65 1.28 5.50 1.71 0.18 0.61
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -27 -35 -35 -31 -25 -32 -23
Debt-free Net Working Capital (DFNWC)		 63 337 274 245 228 213 225
Net Working Capital (NWC)		 63 337 274 243 228 213 225
Net Nonoperating Expense (NNE)		 9.28 24 26 38 35 22 24
Net Nonoperating Obligations (NNO)		 -93 -364 -444 -329 -285 -271 -301
Total Depreciation and Amortization (D&A)		 1.93 1.93 4.09 3.10 -1.50 -3.58 -0.78
Debt-free, Cash-free Net Working Capital to Revenue		 -128.26% -104.03% -76.09% -99.23% -121.69% -90.81% -65.26%
Debt-free Net Working Capital to Revenue		 295.24% 1,015.69% 599.42% 788.84% 1,100.52% 597.43% 626.14%
Net Working Capital to Revenue		 295.24% 1,015.69% 599.42% 781.49% 1,100.52% 597.43% 626.14%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($5.83) ($1.82) ($2.62) ($2.67) ($1.52) ($1.27)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 43.12M 48.74M 48.86M 49.64M 69.37M 82.89M
Adjusted Diluted Earnings per Share		 $0.00 ($5.83) ($1.82) ($2.62) ($2.67) ($1.52) ($1.27)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 43.12M 48.74M 48.86M 49.64M 69.37M 82.89M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($5.83) ($1.82) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 11.37M 46.04M 49.05M 68.60M 70.99M 97.58M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -42 -57 -91 -97 -82 -73
Normalized NOPAT Margin		 -116.07% -127.47% -125.57% -291.59% -468.88% -230.51% -203.47%
Pre Tax Income Margin		 -155.72% -201.72% -183.23% -412.19% -632.17% -295.60% -291.74%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 -53.80 -38.29 0.00 -69.72 0.00 0.00
NOPAT to Interest Expense		 0.00 -34.43 -26.80 0.00 -48.81 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -54.33 -38.89 0.00 -70.58 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -34.96 -27.40 0.00 -49.66 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.09% -0.29% 0.00% 0.00% -0.08% -0.18% -0.18%

Quarterly Metrics And Ratios for C4 Therapeutics

This table displays calculated financial ratios and metrics derived from C4 Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 49,190,855.00 49,281,046.00 49,281,046.00 68,805,786.00 69,337,753.00 70,588,959.00 70,989,661.00 71,007,083.00 71,170,815.00 - 97,578,175.00
DEI Adjusted Shares Outstanding		 49,190,855.00 49,281,046.00 49,281,046.00 68,805,786.00 69,337,753.00 70,588,959.00 70,989,661.00 71,007,083.00 71,170,815.00 - 97,578,175.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.53 -0.69 -0.58 -0.26 -0.36 -0.50 -0.37 -0.37 -0.45 - -0.26
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 63.93% 14.26% -19.15% 350.68% 38.75% 58.76% 138.17% -46.17% -26.90% 112.79% -15.00%
EBITDA Growth		 10.84% 0.09% 8.62% 40.39% -2.76% -0.91% 15.72% -32.91% -18.09% 38.45% -2.26%
EBIT Growth		 14.41% 2.26% 11.07% 42.92% -1.57% -0.75% 9.48% -32.92% -21.84% 38.62% 4.73%
NOPAT Growth		 14.41% 2.26% 11.07% 42.92% -1.57% -0.75% 9.48% -32.92% -21.84% 38.62% 4.73%
Net Income Growth		 15.40% 6.54% 18.46% 50.68% 8.77% 0.52% 7.19% -46.87% -30.41% 40.75% 4.53%
EPS Growth		 15.38% 10.53% 42.25% 64.38% 36.36% 26.47% 9.76% -42.31% -25.71% 82.00% 45.95%
Operating Cash Flow Growth		 -9.59% 17.57% 45.30% 73.82% 21.41% 25.31% -83.71% -142.40% -29.31% -23.49% 10.04%
Free Cash Flow Firm Growth		 115.16% 35.30% 67.01% 65.74% -158.65% 60.18% -65.18% -123.41% -142.68% -152.15% -14.99%
Invested Capital Growth		 0.00% 1.66% -26.90% -13.46% -33.47% -40.24% 2.98% -0.45% -7.98% 19.67% 12.89%
Revenue Q/Q Growth		 315.62% -70.55% -6.81% 295.06% 27.95% -66.30% 39.81% -10.71% 73.76% -1.91% -44.15%
EBITDA Q/Q Growth		 25.27% -33.66% 12.98% 31.41% -28.81% -31.26% 27.32% -8.17% -14.45% 31.59% -20.74%
EBIT Q/Q Growth		 25.98% -34.59% 13.92% 33.45% -31.72% -33.51% 22.66% 2.27% -20.74% 32.74% -20.05%
NOPAT Q/Q Growth		 25.98% -34.59% 13.92% 33.45% -31.72% -33.51% 22.66% 2.27% -20.74% 32.74% -20.05%
Net Income Q/Q Growth		 24.73% -28.54% 18.40% 37.53% -39.23% -40.16% 23.87% 1.15% -23.62% 36.31% -22.66%
EPS Q/Q Growth		 24.66% -23.64% 39.71% 36.59% -34.62% -42.86% 26.00% 0.00% -18.92% 79.55% -122.22%
Operating Cash Flow Q/Q Growth		 -61.64% 21.81% 24.54% 72.55% -385.18% 25.70% -85.62% 63.78% -158.83% 29.04% -35.22%
Free Cash Flow Firm Q/Q Growth		 155.86% -286.64% 51.01% 32.92% 4.38% -26.71% -103.23% 9.27% -3.87% -31.66% 7.32%
Invested Capital Q/Q Growth		 26.30% -15.25% -13.61% -17.58% 13.30% -21.10% 21.40% -21.72% 6.80% 9.92% 14.76%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -256.53% -1,164.18% -1,087.07% -188.73% -189.99% -740.00% -384.66% -465.98% -306.92% -214.05% -462.78%
Operating Margin		 -251.16% -1,147.72% -1,060.18% -178.59% -183.86% -728.39% -402.93% -440.99% -306.43% -210.10% -451.64%
EBIT Margin		 -251.16% -1,147.72% -1,060.18% -178.59% -183.86% -728.39% -402.93% -440.99% -306.43% -210.10% -451.64%
Profit (Net Income) Margin		 -244.19% -1,065.75% -933.23% -147.56% -160.57% -667.82% -363.66% -402.60% -286.43% -185.97% -408.47%
Tax Burden Percent		 103.85% 100.80% 100.00% 100.00% 100.00% 100.38% 100.00% 100.00% 100.00% 100.59% 100.00%
Interest Burden Percent		 93.62% 92.12% 88.03% 82.62% 87.33% 91.34% 90.26% 91.30% 93.47% 87.99% 90.44%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -124.92% -49.50% -48.42% -44.87% -46.00% -45.58% -45.55% -52.99% -59.98% -44.44% -48.35%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -30.69% -59.02% -53.48% -13.88% -17.46% -71.40% -44.66% -44.57% -28.76% -21.31% -48.57%
Return on Assets (ROA)		 -29.84% -54.80% -47.07% -11.47% -15.25% -65.46% -40.31% -40.69% -26.88% -18.87% -43.92%
Return on Common Equity (ROCE)		 -124.92% -49.50% -48.42% -44.87% -46.00% -45.58% -45.55% -52.99% -59.98% -44.44% -48.35%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -19 -26 -23 -15 -20 -26 -20 -20 -24 -16 -19
NOPAT Margin		 -175.81% -803.40% -742.13% -125.02% -128.70% -509.88% -282.05% -308.69% -214.50% -147.07% -316.15%
Net Nonoperating Expense Percent (NNEP)		 -6.06% -2.79% -1.94% -0.94% -1.82% -2.94% -2.18% -2.31% -3.29% -1.50% -2.23%
Return On Investment Capital (ROIC_SIMPLE)		 -9.01% -10.65% -8.73% -6.08% -8.15% -12.22% -10.46% -11.46% -15.60% -6.31% -8.30%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 95.13% 315.76% 338.53% 80.75% 76.60% 200.37% 128.90% 135.65% 79.43% 83.32% 151.67%
R&D to Revenue		 256.02% 931.95% 741.46% 197.84% 207.25% 628.03% 374.03% 405.34% 231.42% 226.78% 399.97%
Operating Expenses to Revenue		 351.16% 1,247.72% 1,160.18% 278.59% 283.86% 828.39% 502.93% 540.99% 406.43% 310.10% 551.64%
Earnings before Interest and Taxes (EBIT)		 -28 -37 -32 -21 -28 -38 -29 -29 -34 -23 -28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -28 -38 -33 -23 -29 -38 -28 -30 -34 -24 -28
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.42 1.13 1.56 1.29 1.63 1.18 0.58 0.58 1.02 0.72 1.10
Price to Tangible Book Value (P/TBV)		 0.42 1.13 1.56 1.29 1.63 1.18 0.58 0.58 1.02 0.72 1.10
Price to Revenue (P/Rev)		 4.50 13.41 20.10 10.82 11.74 7.14 2.86 2.97 5.25 5.15 7.36
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 5.16 0.75 3.29 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.16 -1.15 -1.15 -1.20 -1.17 -1.20 -1.19 -1.25 -1.24 -1.21 -1.19
Leverage Ratio		 1.54 1.51 1.53 1.57 1.55 1.57 1.58 1.61 1.62 1.50 1.51
Compound Leverage Factor		 1.44 1.39 1.34 1.30 1.35 1.44 1.43 1.47 1.51 1.32 1.37
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.12 -0.23 0.23 -0.10 0.12 -0.92 -1.80 -2.21 -2.48 -1.16 -1.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.39 6.34 5.08 5.09 6.31 5.71 5.70 5.06 5.76 7.81 9.00
Quick Ratio		 7.17 6.21 4.94 4.89 6.14 5.49 5.47 4.87 5.52 7.60 8.75
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 14 -27 -13 -8.83 -8.44 -11 -22 -20 -20 -27 -25
Operating Cash Flow to CapEx		 -5,117.83% -15,292.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,592.94% -201,318.18% -46,787.50%
Free Cash Flow to Firm to Interest Expense		 18.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -38.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -39.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.12 0.05 0.05 0.08 0.10 0.10 0.11 0.10 0.09 0.10 0.11
Accounts Receivable Turnover		 0.00 3.13 2.84 26.77 6.21 4.78 3.68 20.60 3.57 13.06 6.39
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 2.86 2.78 4.15 4.99 5.49 6.50 5.65 5.31 6.79 6.99
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 116.70 128.68 13.64 58.76 76.42 99.21 17.72 102.34 27.94 57.12
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 116.70 128.68 13.64 58.76 76.42 99.21 17.72 102.34 27.94 57.12
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -34 -39 -44 -52 -45 -55 -43 -52 -49 -44 -37
Invested Capital Turnover		 -1.20 -0.53 -0.51 -0.60 -0.85 -0.76 -0.91 -0.66 -0.64 -0.73 -0.87
Increase / (Decrease) in Invested Capital		 -34 0.66 -9.40 -6.18 -11 -16 1.32 -0.23 -3.61 11 5.54
Enterprise Value (EV)		 -155 -3.25 103 22 111 -13 -121 -121 -42 -112 -12
Market Capitalization		 91 278 403 318 395 254 114 102 158 185 257
Book Value per Share		 $4.39 $4.99 $3.77 $3.59 $3.50 $3.06 $2.75 $2.45 $2.17 $2.65 $2.40
Tangible Book Value per Share		 $4.39 $4.99 $3.77 $3.59 $3.50 $3.06 $2.75 $2.45 $2.17 $2.65 $2.40
Total Capital		 216 246 258 247 243 216 195 174 154 257 234
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -246 -282 -299 -296 -284 -267 -235 -223 -200 -297 -268
Capital Expenditures (CapEx)		 0.60 0.16 0.00 0.00 -0.01 -0.00 0.00 0.00 0.41 0.01 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -23 -25 -34 -42 -26 -32 -23 -34 -21 -23 -18
Debt-free Net Working Capital (DFNWC)		 193 228 225 222 230 213 192 180 171 225 218
Net Working Capital (NWC)		 193 228 225 222 230 213 192 180 171 225 218
Net Nonoperating Expense (NNE)		 7.57 8.56 5.81 2.71 4.90 8.18 5.91 6.07 8.08 4.28 5.68
Net Nonoperating Obligations (NNO)		 -250 -285 -303 -299 -288 -271 -238 -226 -203 -301 -272
Total Depreciation and Amortization (D&A)		 -0.60 -0.54 -0.82 -1.22 -0.94 -0.60 1.32 -1.62 -0.06 -0.44 -0.69
Debt-free, Cash-free Net Working Capital to Revenue		 -113.78% -121.69% -167.79% -143.83% -76.35% -90.81% -58.75% -100.12% -69.63% -65.26% -50.34%
Debt-free Net Working Capital to Revenue		 950.49% 1,100.52% 1,120.85% 755.13% 682.95% 597.43% 481.90% 526.50% 567.69% 626.14% 625.69%
Net Working Capital to Revenue		 950.49% 1,100.52% 1,120.85% 755.13% 682.95% 597.43% 481.90% 526.50% 567.69% 626.14% 625.69%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.55) ($0.68) ($0.41) ($0.26) ($0.35) ($0.50) ($0.37) ($0.37) ($0.44) ($0.09) ($0.20)
Adjusted Weighted Average Basic Shares Outstanding		 49.21M 49.64M 68.43M 68.81M 69.63M 69.37M 70.83M 71.01M 72.56M 82.89M 126.07M
Adjusted Diluted Earnings per Share		 ($0.55) ($0.68) ($0.41) ($0.26) ($0.35) ($0.50) ($0.37) ($0.37) ($0.44) ($0.09) ($0.20)
Adjusted Weighted Average Diluted Shares Outstanding		 49.21M 49.64M 68.43M 68.81M 69.63M 69.37M 70.83M 71.01M 72.56M 82.89M 126.07M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.28M 68.60M 68.81M 69.34M 70.59M 70.99M 71.01M 71.17M 96.91M 97.58M 110.57M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -26 -21 -15 -20 -26 -20 -20 -17 -16 -19
Normalized NOPAT Margin		 -175.81% -803.40% -686.00% -125.02% -128.70% -509.88% -282.05% -308.69% -147.60% -147.07% -316.15%
Pre Tax Income Margin		 -235.13% -1,057.25% -933.23% -147.56% -160.57% -665.29% -363.66% -402.60% -286.43% -184.87% -408.47%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -35.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -24.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -36.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -25.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.08% -0.08% -0.10% -0.12% -0.18% -0.18% -0.23% -0.22% -0.15% -0.18% -0.23%

Financials Breakdown Chart

Key Financial Trends

C4 Therapeutics (NASDAQ: CCCC) showed meaningful revenue growth in Q1 2026, but the company remains deeply unprofitable and continues to burn cash. Revenue rose to $6.2 million in Q1 2026 from $3.0 million in Q1 2024, but operating losses are still sizable at $27.8 million for the quarter. The balance sheet remains asset-rich thanks to a large cash and investment position, which gives the company runway, but that cushion has been shrinking over the past year.

  • Revenue improved year over year in Q1 2026, increasing to $6.15 million from $3.04 million in Q1 2024, showing better top-line momentum.
  • Cash and investments remain substantial, with $61.3 million in cash and equivalents plus $207.0 million in short- and long-term investments at March 31, 2026.
  • Working capital remains strong, supported by $245.4 million in current assets versus $27.2 million in current liabilities.
  • Interest and investment income helped offset operating losses, contributing $2.7 million in Q1 2026 other income.
  • Operating expenses were slightly lower sequentially than Q4 2025, with total operating expenses of $33.9 million versus $34.2 million.
  • R&D spending remains the main cost driver at $24.6 million in Q1 2026, which is typical for a clinical-stage biotech but keeps losses elevated.
  • Deferred revenue is meaningful at $25.6 million combined current and noncurrent, which may provide some future revenue recognition support.
  • Share count has risen materially over the last year, reflecting dilution from financing activity and/or equity issuance.
  • Net loss remains large at $25.1 million in Q1 2026, only modestly better than the $28.4 million loss in Q1 2024.
  • Operating cash burn is still heavy, with negative operating cash flow of $29.9 million in Q1 2026.
  • Cash and equivalents declined quarter over quarter from $77.9 million in Q2 2025 and $58.8 million in Q3 2025 to $61.3 million in Q1 2026, despite a large investment portfolio.
  • Equity has been eroded by persistent losses and dilution, with retained earnings at negative $763.8 million and common equity falling from $258.3 million in Q1 2024 to $234.2 million in Q1 2026.
  • Investing cash flow was supported by investment sales, not core profitability, which suggests liquidity is being managed through portfolio repositioning rather than operating strength.

Bottom line: C4 Therapeutics has enough liquidity for now and is showing some revenue progress, but the business is still far from break-even. For retail investors, the key questions remain whether its pipeline can translate into sustained revenue growth and whether operating losses can narrow before cash burn becomes a bigger problem.

07/21/26 02:22 AM ETAI Generated. May Contain Errors.

C4 Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, C4 Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

C4 Therapeutics' net income appears to be on an upward trend, with a most recent value of -$104.99 million in 2025, rising from -$34.10 million in 2019. The previous period was -$105.32 million in 2024. Check out C4 Therapeutics' forecast to explore projected trends and price targets.

C4 Therapeutics' total operating income in 2025 was -$115.22 million, based on the following breakdown:
  • Total Gross Profit: $35.95 million
  • Total Operating Expenses: $151.17 million

Over the last 6 years, C4 Therapeutics' total revenue changed from $21.38 million in 2019 to $35.95 million in 2025, a change of 68.1%.

C4 Therapeutics' total liabilities were at $102.49 million at the end of 2025, a 23.3% decrease from 2024, and a 14.0% decrease since 2019.

In the past 6 years, C4 Therapeutics' cash and equivalents has ranged from $29.75 million in 2022 to $181.73 million in 2020, and is currently $74.60 million as of their latest financial filing in 2025.

Over the last 6 years, C4 Therapeutics' book value per share changed from -81.61 in 2019 to 2.65 in 2025, a change of -103.2%.


Related Companies

Financial statements for NASDAQ:CCCC last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel